bevacizumab

URI: https://gptkb.org/entity/bevacizumab

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:monoclonal_antibody anti-angiogenic drug
gptkbp:administeredBy	intravenous infusion
gptkbp:approvedBy	gptkb:FDA gptkb:EMA 2004
gptkbp:ATCCode	L01XC07
gptkbp:biosimilar	gptkb:Alymsys gptkb:Mvasi gptkb:Zirabev Aybintio
gptkbp:brand	gptkb:Avastin
gptkbp:CASNumber	216974-75-3
gptkbp:contraindication	uncontrolled hypertension hypersensitivity to bevacizumab recent surgery
gptkbp:developedBy	gptkb:Genentech
gptkbp:discoveredBy	gptkb:Napoleone_Ferrara
gptkbp:halfLife	20 days
https://www.w3.org/2000/01/rdf-schema#label	bevacizumab
gptkbp:indication	metastatic colorectal cancer persistent, recurrent, or metastatic cervical cancer metastatic renal cell carcinoma non-squamous non-small cell lung cancer recurrent glioblastoma epithelial ovarian, fallopian tube, or primary peritoneal cancer
gptkbp:legalStatus	prescription only
gptkbp:marketedAs	gptkb:Roche
gptkbp:mechanismOfAction	inhibits VEGF-A
gptkbp:molecularWeight	149 kDa
gptkbp:patentExpired	2019 (US)
gptkbp:pregnancyCategory	D (US)
gptkbp:routeOfAdministration	intravenous
gptkbp:sideEffect	bleeding hypertension proteinuria gastrointestinal perforation impaired wound healing
gptkbp:target	gptkb:VEGF-A
gptkbp:type	humanized monoclonal antibody
gptkbp:UNII	82S8T1848I
gptkbp:usedFor	gptkb:non-small_cell_lung_cancer gptkb:cancer gptkb:fallopian_tube_cancer gptkb:glioblastoma colorectal cancer renal cell carcinoma peritoneal cancer
gptkbp:bfsParent	gptkb:F-BVFA gptkb:Lynparza
gptkbp:bfsLayer	5